Currently there are five projects ongoing within the CROES.
The Global PCNL observational study has closed at the end of the year 2009. In this study over 96 sites from Asia, Europe and the Americas participated and in one year these sites prospectively enrolled close to 6000 patients. At this moment eight manuscripts have been finalized. At several occasions (AUA, EAU, WCE) posters have been presented on the PCNL study.
The Global Ureteroscopy observational study has been initiated January 2010. The aim of the URS study is to assess on a global basis the indications and outcomes of both flexible and semi rigid URS. At the moment more than 10.000 patients have been included by more than 150 centers. The study is currently closed for new centers, but data collection is still ongoing.
In the Renal Mass study we aim to assess on a global basis the indications, treatment modality, and outcomes of surgical treatment for renal masses including (open/laparoscopic/robotic) radical or partial nephrectomy and (percutaneous/laparoscopic assisted) tumor ablation using cryo or radiofrequency. By now almost 3000 patients have been included in 120 sites. To our knowledge this is one of the largest prospective international studies on the treatment of renal mass and the steering committee is confident to derive new insights from this work.The study is currently closed for new centers, but data collection is still ongoing.
The CROES Greenlight Laser an observational study on KTP laser for treating benign prostatic hyperplasia. In this prospective study we will study on a global base the indications and outcomes of HPS greenlight laser treatment for BPH. At the moment there are 30 centers actively participating with almost 900 patients included.The study is currently closed for new centers, but data collection is still ongoing.
The latest projects is the CROES NBI study: This is the first randomized study coordinated by CROES. Forty sites have confirmed to participate and we aim at including 1000 patients worldwide.This is a randomized study and compares the recurrence rate at 1 year following Narrow Band Imaging and TURB with White Light Trans Urethral Resection of Bladder cancer (TURB) in patients with bladder cancer (NMIBC). At present 11 centers are actively participating and have included 120 patients. CROES expects more centers will follow shortly, as many of them are currently in process of obtaining IRB approval.